A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Email
Print
Home > Medical Reference > Patient Education
Ask the Expert
Get answers to your Ulcerative Colitis questions.
Dr. Flasar’s Bio | Q&A Archive
Related Content
Ulcerative colitis - Risk Factors
Description
An in-depth report on the causes, diagnosis, treatment, and prevention of ulcerative colitis.Alternative Names
Inflammatory bowel disease - ulcerative colitis; Colitis - ulcerative
Risk Factors:
About 1 million Americans suffer from inflammatory bowel disease (IBD), and about half of these patients have ulcerative colitis. There are several risk factors for ulcerative colitis.
Age
Ulcerative colitis can occur at any age, but it is most often diagnosed in people ages 15 - 35 and, less commonly, in people ages 50 - 75.
Gender
Men and women are equally at risk for developing ulcerative colitis.
Family History
Ulcerative colitis tends to run in families, with up to 20% of patients having a close relative who also has the disease.
Race and Ethnicity
Ulcerative colitis is more common among whites than non-whites. Jewish people of Ashkenzi (Eastern European) descent have a heightened risk for ulcerative colitis.
Smoking
Smoking appears to increases the risk of developing Crohn's disease, and can worsen the course of the disease. Conversely, smoking appears to decrease the risk of developing ulcerative colitis. Because of the hazards of smoking, however, it should never be used to protect against ulcerative colitis.
Resources
- www.ccfa.org -- Crohn's & Colitis Foundation of America
- www.gastro.org -- American Gastroenterological Association
- www.acg.gi.org -- American College of Gastroenterology
- www2.niddk.nih.gov -- National Digestive Diseases Information Clearinghouse
References
Baumgart DC and Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-57.
Chande N, MacDonald JK and McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):CD006618.
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul;133(1):312-39.
Langan RC, Gotsch PB, Krafczyk MA and Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007; 76(9):1323-30.
Mahid SS, Minor KS, Soto RE, Hornung CA and Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462-71.
Mallon P, McKay D, Kirk S and Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):CD005573.
- Reviewed last on: 12/1/2008
- Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
Click to Print
Print Preview
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885
